-
(Neurogenetics lab) and in collaboration with Professor Joanne Ng (Genetic Therapy Accelerator Centre) and Professor Fiona Ducotterd (ARUK UCL Drug Discovery Institute). Biallelic AAGGG expansions in RFC1
-
the underlying mechanisms leading to the epilepsies and associated comorbidities in each individual person. Our vision is to build upon the excellence and breadth of our research, seamlessly integrating basic and
-
organoid models of neurodevelopmental diseases to test advanced genetic therapies. It will be supervised by Professor Gabriele Lignani and is in collaboration with Dr Amy McTague at UCL Institute of Child
-
biomarker collection and MRI imaging. Both the EJS ACT-PD Trial and Initiative are led by Professor Camille Carroll (Newcastle University, Co-Chief investigator) and Professor Thomas Foltynie (UCL, Co-Chief
-
the study teams and Professor Camille Carroll on the EJS ACT-PD trial. Identifying a disease-modifying therapy (DMT) for Parkinson’s disease (PD) is a major unmet need. The Edmond J Safra Accelerating
-
the underlying mechanisms leading to the epilepsies and associated comorbidities in each individual person. Our vision is to build upon the excellence and breadth of our research, seamlessly integrating basic and
-
: Implementation Process Evaluation, which is led by Professor Justin Waring and works closely with service stakeholders, LEAG members, and the programme’s clinical and technical leads. The research will apply